Search Results for “cancer” – Page 41 – media

prioritizing efficacy when considering quality of life

It is an exciting yet challenging time to be a treating physician in oncology, particularly in kidney cancer. The last decade of scientific innovation has brought an unprecedented shift in treatment options, and people now live longer than before with kidney cancer. Despite this, kidney cancers are the tenth most common cancer globally, with renal cell carcinoma (RCC) the most common type of kidney cancer, making up about 85% of diagnoses. There is no known cure for people living with advanced RCC, and the 5-year survival rate is around 12%, demonstrating the importance of continuing to find new innovative treatments. The introduction of next-generation tyrosine kinase inhibitors, immunotherapy-based agents, and, more recently, combination therapies have transformed the clinical outcomes of people living with RCC. However, with innovation comes more choice and increasingly complex therapeutic decision-making – often raising questions around the optimal sequence of treatments, particularly in more advanced ...
- Source: drugdu
- 226
- March 30, 2023
Roche Holding AG Receives FDA Approval for New Cancer Treatment

Roche Holding AG, a Swiss multinational healthcare company, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for its new cancer treatment. The drug, known as Polivy, is designed to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma. This approval is significant for Roche, as DLBCL is one of the most common types of non-Hodgkin’s lymphoma and a highly aggressive form of cancer. Polivy is a first-in-class antibody-drug conjugate that targets CD79b, a protein that is highly expressed on the surface of B-cell lymphomas. The drug is designed to bind to the CD79b protein and deliver a toxic payload directly to cancer cells, without affecting healthy cells. This approach is known as targeted therapy and is considered to be a significant advancement in cancer treatment. The FDA’s decision was based on the results of a phase ...
- Source: drugdu
- 140
- March 24, 2023
All hormonal contraceptives ‘carry small increased risk of breast cancer’

Research finds use of progestogen is associated with a 20-30% higher risk but this falls after no longer taking it All types of hormonal contraceptives carry a small increased risk of breast cancer, according to research establishing a link with progestogen pills for the first time. The use of progestogen is associated with a 20-30% higher risk of breast cancer, data analysis by University of Oxford researchers has established. This builds on previous work showing that use of the combined contraceptive pill, which contains oestrogen and progestogen, is associated with a small increase in the risk of developing breast cancer that declines after stopping taking it. Claire Knight of Cancer Research UK, which funded the study, said the risk was small and should not discourage most people from taking the pill. She said: “Women who are most likely to be using contraception are under the age of 50, where the risk of ...
- Source: drugdu
- 118
- March 22, 2023
Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

Pfizer and Astellas have reported positive top line results from a phase 3 trial of their androgen receptor signalling inhibitor, Xtandi (enzalutamide), in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR). The medicine is already a standard of care in the US for metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), and for one or more of these indications in more than 100 countries. Compared with those indications, nmHSPC represents an earlier stage of disease, in which there is no detectable evidence of the cancer spreading to distant parts of the body, and it still responds to testosterone-lowering treatments. However, some patients remain at a higher risk for BCR following primary treatment, which may result in metastases. The EMBARK trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated daily ...
- Source: drugdu
- 146
- March 21, 2023
New Drug Combination Shows Promise in Treating Lung Cancer

Researchers from the University of Texas MD Anderson Cancer Center have found that a combination of two drugs may be effective in treating non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and accounts for approximately 85% of all lung cancer cases. The study, published in the journal Nature Medicine, involved analyzing data from over 1,000 patients with NSCLC. The researchers identified a group of genes that were associated with resistance to immunotherapy, a type of cancer treatment that uses the body’s immune system to fight cancer cells. The researchers then tested a combination of two drugs, a checkpoint inhibitor and a targeted therapy, in mouse models of NSCLC. The checkpoint inhibitor works by releasing the brakes on the immune system, allowing it to attack cancer cells. The targeted therapy works by inhibiting a protein that is overexpressed in many types of cancer ...
- Source: drugdu
- 121
- March 21, 2023
New Study Shows Promising Results for Targeted Cancer Therapy

A recent study published in the Journal of Clinical Oncology has shown promising results for a new type of cancer therapy. The therapy, known as a targeted therapy, uses drugs that specifically target the genetic mutations that drive the growth of cancer cells. Traditional cancer treatments like chemotherapy and radiation therapy are often associated with serious side effects because they damage healthy cells along with cancer cells. Targeted therapies, on the other hand, are designed to be more precise and have fewer side effects. The new study focused on a targeted therapy called larotrectinib, which is designed to treat cancers that have a specific genetic mutation called NTRK fusion. NTRK fusion is a rare but important genetic alteration that is found in a variety of cancers, including certain types of lung, colon, and breast cancer. The study included 55 patients with NTRK fusion-positive cancer who were treated with larotrectinib. The ...
- Source: drugdu
- 171
- March 20, 2023
New Study Shows Potential for Personalized Treatment for Lung Cancer

Lung cancer is a leading cause of cancer-related death worldwide, and treatment options are limited for patients with advanced disease. However, a recent study published in the journal Nature has shown promising results for a new approach to treating lung cancer using personalized medicine. The researchers analyzed the genomes of more than 2,000 patients with non-small cell lung cancer and identified several genetic mutations that were associated with a better response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer. The researchers also developed a personalized treatment algorithm that took into account the genetic mutations of each patient’s tumor. They found that patients who received personalized treatment based on their tumor’s genetic profile had a better response to immunotherapy than those who received standard treatment. The lead author of the study, Dr. Trever Bivona, said that the results were “very promising” and showed that personalized ...
- Source: drugdu
- 158
- March 20, 2023
Scientists identify link between genetic changes and rare childhood cancer rhabdomyosarcoma

Genetic changes may help to improve decision making for the treatment of the rare and aggressive form of childhood cancer rhabdomyosarcoma, according to a new international study led by researchers at the Institute of Cancer Research, London (ICR). The study analysed the DNA from 641 patients with rhabdomyosarcoma – a rare and aggressive type of childhood cancer that resembles muscle tissue and mostly affects children. According to ICR, less than 30% of children with this type of cancer who have relapsed and whose disease has spread will survive. There are two main subtypes of rhabdomyosarcoma, including fusion gene-positive and fusion gene-negative, depending on the presence of a ‘fusion gene’. Researchers found that, when looking at those with fusion-negative rhabdomyosarcoma, children whose tumours had faults in the genes MYOD1 and TP53 had significantly poorer response to treatment and worse survival outcomes. The TP53 gene was found to be altered in 69 ...
- Source: drugdu
- 167
- June 28, 2021
rhabdomyosarcoma
Alchemab to collaborate with AstraZeneca on prostate cancer research

Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer. As part of the collaboration, Alchemab and AZ will collaborate on a proof-of-concept study to improve understanding of the ‘fundamental biology’ of prostate cancer. Alchemab will utilise its novel drug discovery platform as a diagnostic tool through the identification of disease biomarkers, with the potential to inform the development of new antibody-based medications. Under the agreement, Alchemab will sequence and explore antibody repertoires in patient samples gathered from a clinical trial of an undisclosed immuno-oncology agent within AZ’s pipeline. Alchemab may also be able to identify antibody sequence patterns that could be used as biomarkers for early detection and patient stratification by classifying patients into two groups – responders and non-responders. The overall purpose of the collaboration is to identify novel and disease-relevant antibodies which may generate therapeutic insights into ...
- Source: drugdu
- 369
- May 7, 2021
AstraZeneca
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer

Gilead’s antibody drug conjugate (ADC) Trodelvy has received an accelerated approval from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer. The approval covers the use of Trodelvy (sacituzumab govitecan-hziy) in patients with advanced UC who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor. Trodelvy was approved on the basis of results from Gilead’s Phase II TROPHY study, which evaluated the drug as monotherapy or as a combination therapy in patients with metastatic UC after progression on a platinum-based chemotherapy and PD-1/L1 inhibitor. In 112 patients who were evaluable for efficacy, 27.7% of those who were treated with Trodelvy responded to treatment, with 5.4% experiencing a complete response and 22.3% experiencing a partial response. The study also found a median duration of response of 7.2 months for those treated ...
- Source: drugdu
- 174
- April 15, 2021
bladder cancer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.